Ali Nael1, William W Wu2, Imran Siddiqi3, Xiaohui Zhao4, Kanwarpal S Kahlon5, Sherif A Rezk6. 1. Department of Pathology, Children's Hospital of Orange County (CHOC), Orange, California, USA. 2. Department of Pathology and Laboratory Medicine, Kaiser Permanente Fontana Medical Center, Fontana, CA, USA. 3. Department of Pathology and Laboratory Medicine, University of Southern California (USC), USA. 4. Department of Pathology and Laboratory Medicine, University of California Irvine (UCI), Irvine, CA, USA. 5. Division of Hematology-Oncology, University of California Los Angeles (UCLA), Los Angeles, CA, USA. 6. Department of Pathology and Laboratory Medicine, University of California Irvine (UCI), Irvine, CA, USA. srezk@uci.edu.
Abstract
AIMS: Epstein-Barr virus (EBV) expression has been reported in several hematopoietic and non-hematopoietic disorders but its expression in plasma cell neoplasms has been largely limited to immunodeficiency-related cases such as in the setting of post-organ transplantation or human immunodeficiency virus (HIV) infection. The aim of this study is to evaluate the association of EBV with plasma cell neoplasms, mainly in immunocompetent patients. METHODS AND RESULTS: We retrospectively studied 147 cases of patients with different plasma cell neoplasms (109 plasma cell myelomas, 22 plasmacytomas, and 16 monoclonal gammopathy cases). Six patients were immunocompromised. EBV was positive in 6 cases; 3 immunocompromised (2 patients with HIV infection and 1 patient was post-renal transplant) and 3 immunocompetent patients with plasmacytoma and variable plasmablastic features. CONCLUSIONS: Our data shows that EBV was negative in all plasma cell myeloma cases in immunocompetent patients and has an overall low association with the different plasma cell neoplasms in the immunocompetent setting. When expressed, it is usually associated with variable plasmablastic features.
AIMS: Epstein-Barr virus (EBV) expression has been reported in several hematopoietic and non-hematopoietic disorders but its expression in plasma cell neoplasms has been largely limited to immunodeficiency-related cases such as in the setting of post-organ transplantation or human immunodeficiency virus (HIV) infection. The aim of this study is to evaluate the association of EBV with plasma cell neoplasms, mainly in immunocompetent patients. METHODS AND RESULTS: We retrospectively studied 147 cases of patients with different plasma cell neoplasms (109 plasma cell myelomas, 22 plasmacytomas, and 16 monoclonal gammopathy cases). Six patients were immunocompromised. EBV was positive in 6 cases; 3 immunocompromised (2 patients with HIV infection and 1 patient was post-renal transplant) and 3 immunocompetent patients with plasmacytoma and variable plasmablastic features. CONCLUSIONS: Our data shows that EBV was negative in all plasma cell myeloma cases in immunocompetent patients and has an overall low association with the different plasma cell neoplasms in the immunocompetent setting. When expressed, it is usually associated with variable plasmablastic features.
Authors: Marie Donzel; Maxime Bonjour; Jean-Damien Combes; Florence Broussais; Pierre Sesques; Alexandra Traverse-Glehen; Catherine de Martel Journal: EClinicalMedicine Date: 2022-10-01